Skip to Content

86 Results Found

  • Article
  • Open Access
9 Citations
3,574 Views
13 Pages

The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis

  • Lianqun Qiu,
  • L. Jeffrey Medeiros,
  • Guilin Tang,
  • Mahsa Khanlari and ,
  • Shaoying Li,
  • Sergej Konoplev,
  • Sa A. Wang,
  • C. Cameron Yin,
  • Joseph D. Khoury and
  • Jie Xu
  • + 9 authors+ 4 authors

16 December 2021

Patients with anaplastic large cell lymphoma (ALCL) rarely develop a leukemic phase of the disease. The reported leukemic ALCL cases are almost all ALK-positive, which are frequently associated with small cell morphology, t(2;5)(p23;q35), and a poore...

(This article belongs to the Special Issue Molecular Pathogenesis and Management of Anaplastic Large Cell Lymphoma)
  • Case Report
  • Open Access
4 Citations
1,271 Views
4 Pages

Brentuximab Vedotin for Refractory Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma in Leukemic Phase with RUNX3 Overexpression

  • Yusuke Yamashita,
  • Yoshikazu Hori,
  • Hideki Kosako,
  • Takehiro Oiwa and ,
  • Kenji Warigaya,
  • Toshiki Mushino,
  • Shogo Murata,
  • Masakazu Fujimoto,
  • Akinori Nishikawa and
  • Shinobu Tamura
  • + 7 authors+ 2 authors

Anaplastic lymphoma kinase (ALK)- negative anaplastic large cell lymphoma (ALCL) is an aggressive CD30-positive non- Hodgkin lymphoma. ALK-ALCL rarely manifests with extensive bone marrow and peripheral blood involvement (known as “leukemic phase”)....

  • Case Report
  • Open Access
5 Citations
600 Views
4 Pages

A Rare Case of De Novo CD5+ Diffuse Large B-Cell Lymphoma in Leukemic Phase and Positive for CD13

  • Giovanni Carulli,
  • Eugenio Mario Ciancia,
  • Francesco Caracciolo,
  • Paola Sammuri and ,
  • Cristiana Domenichini,
  • Maria Immacolata Ferreri,
  • Alessia Di Vita,
  • Virginia Ottaviano,
  • Martina Rousseau and
  • Mario Petrini
  • + 5 authors+ 0 author

3 January 2018

We report a case of de novo diffuse large B-cell lymphoma (DLBCL) in leukemic phase, positive for both CD5 and CD13. Morphologic evaluation, flow cytometric immunophenotyping, karyotyping and polymerase chain reaction studies were performed. Neoplast...

  • Article
  • Open Access
11 Citations
3,948 Views
11 Pages

Janerin Induces Cell Cycle Arrest at the G2/M Phase and Promotes Apoptosis Involving the MAPK Pathway in THP-1, Leukemic Cell Line

  • Mohammad Z. Ahmed,
  • Fahd A. Nasr,
  • Wajhul Qamar,
  • Omar M. Noman and ,
  • Javed Masood Khan,
  • Abdullah A. Al-Mishari and
  • Ali S. Alqahtani
  • + 2 authors+ 0 author

13 December 2021

Janerin is a cytotoxic sesquiterpene lactone that has been isolated and characterized from different species of the Centaurea genus. In this study, janerin was isolated form Centaurothamnus maximus, and its cytotoxic molecular mechanism was studied i...

(This article belongs to the Special Issue Natural Products: From Isolation and Identification to Biological Activity—Second Edition)
  • Article
  • Open Access
4 Citations
3,518 Views
35 Pages

Volatile Phases Derived from Serum, DC, or MLC Culture Supernatants to Deduce a VOC-Based Diagnostic Profiling Strategy for Leukemic Diseases

  • Tobias Baudrexler,
  • Tobias Boeselt,
  • Lin Li,
  • Sophia Bohlscheid and ,
  • Ursel Boas,
  • Christoph Schmid,
  • Andreas Rank,
  • Jörg Schmohl,
  • Rembert Koczulla and
  • Helga Maria Schmetzer
  • + 5 authors+ 0 author

14 June 2023

Volatile organic compounds (VOCs) reflect the metabolism in healthy and pathological conditions, and can be collected easily in a noninvasive manner. They are directly measured using electronical nose (eNose), and may qualify as a systemic tool to mo...

(This article belongs to the Section Molecular Biomarkers)
  • Review
  • Open Access
70 Citations
10,855 Views
24 Pages

Genetic lesions predisposing to pediatric B-cell acute lymphoblastic leukemia (B-ALL) arise in utero, generating a clinically silent pre-leukemic phase. We here reviewed the role of the surrounding bone marrow (BM) microenvironment in the persistence...

(This article belongs to the Special Issue Tumor Microenvironment: Interactions and Therapeutic Response)
  • Article
  • Open Access
22 Citations
7,468 Views
14 Pages

Euphorbia formosana Root Extract Induces Apoptosis by Caspase-Dependent Cell Death via Fas and Mitochondrial Pathway in THP-1 Human Leukemic Cells

  • Yi-Jen Hsieh,
  • Chih-Jui Chang,
  • Chin-Feng Wan,
  • Chin-Piao Chen and ,
  • Yi-Han Chiu,
  • Yann-Lii Leu and
  • Kou-Cheng Peng
  • + 2 authors+ 0 author

1 February 2013

Acute myeloid leukemia (AML), a very rare type of cancer, generally affects patients over 50 years old. While clinical drugs to treat advanced stages of AML exist, the disease becomes increasingly resistant to therapies. Euphorbia formosana Hayata (E...

  • Article
  • Open Access
158 Citations
13,428 Views
16 Pages

Structures of Phytosterols and Triterpenoids with Potential Anti-Cancer Activity in Bran of Black Non-Glutinous Rice

  • Panawan Suttiarporn,
  • Watcharapong Chumpolsri,
  • Sugunya Mahatheeranont,
  • Suwaporn Luangkamin and ,
  • Somsuda Teepsawang and
  • Vijittra Leardkamolkarn
  • + 1 author+ 0 author

6 March 2015

Structures of some bioactive phytochemicals in bran extract of the black rice cv. Riceberry that had demonstrated anti-cancer activity in leukemic cell line were investigated. After saponification with potassium hydroxide, separation of the unsaponi...

  • Article
  • Open Access
6 Citations
3,848 Views
13 Pages

Background and objectives: The multidrug resistance protein 4 (MRP4) is a member of the ABC transporter, which has been extensively related to many types of cancer including leukemia. MRP4 overexpression and activity over the efflux of some chemother...

(This article belongs to the Topic Cancer Biology and Radiation Therapy)
  • Review
  • Open Access
1,437 Views
25 Pages

The Role of the Bone Marrow Microenvironment in the Pathogenesis of Acute Myeloid Leukemia

  • Michele Gottardi,
  • Federico De Marchi,
  • Giulia Ciotti,
  • Marco Basso and ,
  • Vittoria Raimondi,
  • Vincenzo Ciminale,
  • Giorgia Simonetti,
  • Martina Ghetti,
  • Rosa Di Liddo and
  • Alessandra Sperotto
  • + 7 authors+ 2 authors

Acute myeloid leukemia (AML) develops within a bone marrow environment that influences leukemic stem cell behavior, residual disease, and response to therapy. This review examines evidence that the marrow microenvironment is not only a site of leukem...

(This article belongs to the Special Issue Pathogenesis, Diagnosis and Treatment of Hematologic Malignancies (2nd Edition))
  • Article
  • Open Access
9 Citations
4,133 Views
14 Pages

Metabolic Profiling during Acute Myeloid Leukemia Progression Using Paired Clinical Bone Marrow Serum Samples

  • Hyun Kyu Kim,
  • Su Young Son,
  • Jae Sang Oh,
  • Ye Na Song and ,
  • Ja Min Byun,
  • Youngil Koh,
  • Junshik Hong,
  • Sung-Soo Yoon,
  • Choong Hwan Lee and
  • Man Ryul Lee
  • + 6 authors+ 1 author

31 August 2021

Cellular metabolic changes reflect the characteristics of patients with acute myeloid leukemia (AML) caused by genetic variations, which are important in establishing AML treatment. However, little is known about the metabolic profile of patients wit...

(This article belongs to the Section Endocrinology and Clinical Metabolic Research)
  • Article
  • Open Access
11 Citations
4,755 Views
15 Pages

Bersavine: A Novel Bisbenzylisoquinoline Alkaloid with Cytotoxic, Antiproliferative and Apoptosis-Inducing Effects on Human Leukemic Cells

  • Darja Koutova,
  • Monika Kulhava,
  • Radim Havelek,
  • Martina Majorosova and ,
  • Karel Královec,
  • Klara Habartova,
  • Anna Hošťálková,
  • Lubomír Opletal,
  • Lucie Cahlikova and
  • Martina Řezáčová
  • + 5 authors+ 0 author

20 February 2020

Bersavine is the new bisbenzylisoquinoline alkaloid isolated from the Berberis vulgaris L. (Berberidaceae) plant. The results of cytotoxicity screening 48 h post-treatment showed that bersavine considerably inhibits the proliferation and viability of...

  • Review
  • Open Access
23 Citations
11,724 Views
35 Pages

Location First: Targeting Acute Myeloid Leukemia Within Its Niche

  • Alice Pievani,
  • Marta Biondi,
  • Chiara Tomasoni,
  • Andrea Biondi and
  • Marta Serafini

Despite extensive research and development of new treatments, acute myeloid leukemia (AML)-backbone therapy has remained essentially unchanged over the last decades and is frequently associated with poor outcomes. Eradicating the leukemic stem cells...

(This article belongs to the Special Issue Advances in Acute Myeloid Leukemia)
  • Article
  • Open Access
21 Citations
3,958 Views
20 Pages

The Anticancer Effect of a Flavonoid-Rich Extract of Bergamot Juice in THP-1 Cells Engages the SIRT2/AKT/p53 Pathway

  • Alessandro Maugeri,
  • Caterina Russo,
  • Laura Musumeci,
  • Giovanni Enrico Lombardo and ,
  • Giovambattista De Sarro,
  • Davide Barreca,
  • Santa Cirmi and
  • Michele Navarra
  • + 3 authors+ 0 author

Novel targets are constantly sought to fight hematologic malignancies. In this regard, high levels of SIRT2 expression are associated with unfavorable prognosis of acute myeloid leukemia. The interest in the plant kingdom has allowed the identificati...

(This article belongs to the Special Issue Pharmaceutical Applications of Plant Extracts)
  • Article
  • Open Access
11 Citations
4,075 Views
21 Pages

Enhancing Therapeutic Efficacy of Double Negative T Cells against Acute Myeloid Leukemia Using Idelalisib

  • Hyeonjeong Kang,
  • Jong Bok Lee,
  • Ismat Khatri,
  • Yoosu Na and ,
  • Cheryl D’Souza,
  • Andrea Arruda,
  • Mark D. Minden and
  • Li Zhang
  • + 3 authors+ 0 author

9 October 2021

The double negative T cell (DNT) is a unique subset of T cells with potent anti-leukemic potential. Previously, DNT therapy has been shown to effectively target AML cells in patient-derived xenograft (PDX) models. Further, a recently completed phase...

(This article belongs to the Special Issue Targeting the Innate Immune Cells in Cancers)
  • Review
  • Open Access
28 Citations
7,352 Views
19 Pages

Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment

  • Olumide Babajide Gbolahan,
  • Amer M. Zeidan,
  • Maximilian Stahl,
  • Mohammad Abu Zaid and ,
  • Sherif Farag,
  • Sophie Paczesny and
  • Heiko Konig
  • + 2 authors+ 0 author

Intensive chemotherapeutic protocols and allogeneic stem cell transplantation continue to represent the mainstay of acute myeloid leukemia (AML) treatment. Although this approach leads to remissions in the majority of patients, long-term disease cont...

(This article belongs to the Special Issue The Biology and Treatment of Myeloid Leukaemias)
  • Article
  • Open Access
1,340 Views
15 Pages

The Prognostic Value of the CD8+PD-1+/CD4+PD-1+ (PERLS) Ratio for Leukemic Transformation in MDS

  • Panagiotis Panagiotidis,
  • Emmanuel Karavanis,
  • Konstantinos Neanidis,
  • Eleftherios Panteris and
  • Maria Moysidou

Background/Objectives: Myelodysplastic syndromes (MDS) are associated with a significant risk of progression to acute myeloid leukemia (AML), affecting approximately 30% of patients. In high-risk MDS, leukemic transformation may occur within a short...

  • Case Report
  • Open Access
889 Views
11 Pages

Critical Role of Molecular-Based Stratification in Low-Risk Myelodysplastic Syndrome with Direct Progression to Acute Myeloid Leukemia: A Case Report

  • Stejara Nicoleta Mihai,
  • Denisa Dragu,
  • Cristina Mambet,
  • Anca Botezatu and ,
  • Petruta Gurban,
  • Laura G. Necula,
  • Lilia Matei,
  • Ana Iulia Neagu,
  • Ioana Pitica and
  • Ana Maria Vladareanu
  • + 12 authors+ 7 authors

The genomic landscape of myelodysplastic syndromes/neoplasms (MDS), a heterogeneous group of myeloid malignancies defined by bone marrow cell dysplasia with ineffective hematopoiesis, includes somatic and, less frequently, germline mutations in hemat...

(This article belongs to the Special Issue Advances in Molecular Target and Anti-Cancer Therapies)
  • Article
  • Open Access
5 Citations
3,018 Views
15 Pages

12 January 2024

Acute myeloid leukemia carrying FMS-like tyrosine kinase receptor-3 (FLT3) mutations is a fatal blood cancer with a poor prognosis. Although the FLT3 inhibitor gilteritinib has recently been approved, it still suffers from limited efficacy and relati...

(This article belongs to the Section Biobased and Biodegradable Polymers)
  • Review
  • Open Access
60 Citations
7,898 Views
13 Pages

Myeloproliferative neoplasms represent a heterogenous group of disorders of the hematopoietic stem cell, with an intrinsic risk of evolution into acute myeloid leukemia. The frequency of leukemic evolution varies according to myeloproliferative neopl...

(This article belongs to the Special Issue Advances in Molecular Biology and Targeted Therapy of Leukemias)
  • Review
  • Open Access
18 Citations
5,264 Views
23 Pages

30 December 2022

It is now well known that the bone marrow (BM) cell niche contributes to leukemogenesis, but emerging data support the role of the complex crosstalk between AML cells and the BM microenvironment to induce a permissive immune setting that protects leu...

(This article belongs to the Collection Mechanism of Immunotherapy in Cancers)
  • Article
  • Open Access
15 Citations
3,609 Views
13 Pages

Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation

  • Joseph D. Khoury,
  • Mehrnoosh Tashakori,
  • Hong Yang,
  • Sanam Loghavi and ,
  • Ying Wang,
  • Jing Wang,
  • Sujan Piya and
  • Gautam Borthakur
  • + 3 authors+ 0 author

25 November 2020

RAF molecules play a critical role in cell signaling through their integral impact on the RAS/RAF/MEK/ERK signaling pathway, which is constitutively activated in a sizeable subset of acute myeloid leukemia (AML) patients. We evaluated the impact of p...

  • Review
  • Open Access
17 Citations
9,299 Views
21 Pages

Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success

  • Ilaria M. Michelozzi,
  • Efstratios Kirtsios and
  • Alice Giustacchini

5 June 2021

Current treatment outcome for acute myeloid leukemia (AML) patients is unsatisfactory and characterized by high rates of relapse and poor overall survival. Increasing evidence points to a crucial role of leukemic stem cells (LSC) and the bone marrow...

(This article belongs to the Special Issue Stem Cells in Leukemia: From Biological Properties to Therapeutic Targeting)
  • Article
  • Open Access
14 Citations
4,433 Views
13 Pages

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia

  • Thomas Cluzeau,
  • Nathan Furstoss,
  • Coline Savy,
  • Wejdane El Manaa and ,
  • Marwa Zerhouni,
  • Lauriane Blot,
  • Anne Calleja,
  • Maeva Dufies,
  • Alix Dubois and
  • Patrick Auberger
  • + 16 authors+ 11 authors

25 December 2019

Myelodysplastic syndrome (MDS) defines a group of heterogeneous hematologic malignancies that often progresses to acute myeloid leukemia (AML). The leading treatment for high-risk MDS patients is azacitidine (Aza, Vidaza®), but a significant prop...

(This article belongs to the Special Issue Drug Resistance in Hematologic Malignancies)
  • Article
  • Open Access
8 Citations
3,740 Views
21 Pages

Acid Ceramidase Inhibitor LCL-805 Antagonizes Akt Signaling and Promotes Iron-Dependent Cell Death in Acute Myeloid Leukemia

  • Johnson Ung,
  • Su-Fern Tan,
  • Todd E. Fox,
  • Jeremy J. P. Shaw and ,
  • Maansi Taori,
  • Bethany J. Horton,
  • Upendarrao Golla,
  • Arati Sharma,
  • Zdzislaw M. Szulc and
  • David J. Feith
  • + 10 authors+ 5 authors

15 December 2023

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy requiring urgent treatment advancements. Ceramide is a cell-death-promoting signaling lipid that plays a central role in therapy-induced cell death. We previously determined that ac...

(This article belongs to the Special Issue Targeting the Sphingolipid Metabolic Pathway: Promotion from Benchwarmer to the Starting Lineup—a Themed Issue in Memory of Drs. Lina Obeid and Mark Kester)
  • Review
  • Open Access
18 Citations
5,645 Views
13 Pages

Myeloid Leukemia of Down Syndrome

  • Aikaterini Kosmidou,
  • Athanasios Tragiannidis and
  • Eleni Gavriilaki

21 June 2023

Myeloid leukemia of Down syndrome (ML-DS) is characterized by a distinct natural history and is classified by the World Health Organization (WHO) as an independent entity, occurring with unique clinical and molecular features. The presence of a long...

(This article belongs to the Special Issue Hematologic Malignancies: Challenges from Diagnosis to Treatment)
  • Article
  • Open Access
7 Citations
5,109 Views
11 Pages

4 September 2019

Adenoviral viral vectors have been widely used for gene-based therapeutics, but commonly used serotype 5 shows poor transduction efficiency into hematopoietic cells. In this study, we aimed to generate a recombinant adenovirus serotype 5 (rAd5) vecto...

(This article belongs to the Special Issue New Insights into Parvovirus Research)
  • Review
  • Open Access
29 Citations
6,326 Views
17 Pages

8 July 2023

Since the introduction of all-trans retinoic acid (ATRA), acute promyelocytic leukemia (APL) has become a highly curable malignancy, especially in combination with arsenic trioxide (ATO). ATRA’s success has deepened our understanding of the rol...

(This article belongs to the Special Issue Acute Promyelocytic Leukemia (APML))
  • Review
  • Open Access
555 Views
61 Pages

23 September 2026

The BCR::ABL1 fusion oncoprotein is the molecular hallmark and principal oncogenic driver of chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKIs) have transformed CML into a largely manageable chronic disease, yet acquired resistance, pe...

(This article belongs to the Special Issue Tumor Therapy and Drug Delivery: 2nd Edition)
  • Review
  • Open Access
14 Citations
6,327 Views
10 Pages

3 July 2022

Myelofibrosis (MF) is the most symptomatic form of myeloproliferative neoplasm and carries the worst outcome. Allogeneic hematopoietic stem cell transplantation is the only therapy with potential for cure at present, but is limited by significant mor...

(This article belongs to the Section Cellular Pathology)
  • Review
  • Open Access
23 Citations
4,355 Views
13 Pages

23 January 2021

The evolution to blast phase is a frequently unpredictable and almost invariably fatal event in the course of myeloproliferative neoplasms. The molecular mechanisms underlying blast transformation have not been elucidated and the specific genetic and...

  • Review
  • Open Access
20 Citations
9,231 Views
21 Pages

6 March 2023

Treatment for acute myeloid leukemia (AML) has evolved rapidly over the last decade as improved understanding of cytogenetic and molecular drivers of leukemogenesis refined survival prognostication and enabled development of targeted therapeutics. Mo...

(This article belongs to the Special Issue Acute Myeloid Leukemia: The Future Is Bright)
  • Article
  • Open Access
29 Citations
4,944 Views
17 Pages

Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia

  • Andrea Ghelli Luserna Di Rorà,
  • Matteo Bocconcelli,
  • Anna Ferrari,
  • Carolina Terragna and ,
  • Samantha Bruno,
  • Enrica Imbrogno,
  • Neil Beeharry,
  • Valentina Robustelli,
  • Martina Ghetti and
  • Giovanni Martinelli
  • + 13 authors+ 8 authors

25 October 2019

Introduction: Screening for synthetic lethality markers has demonstrated that the inhibition of the cell cycle checkpoint kinases WEE1 together with CHK1 drastically affects stability of the cell cycle and induces cell death in rapidly proliferating...

(This article belongs to the Special Issue DNA Damage and Repair in Cancers)
  • Article
  • Open Access
53 Citations
6,509 Views
19 Pages

3 April 2020

Differentiation therapy is an alternative strategy used to induce the differentiation of blast cells toward mature cells and to inhibit tumor cell proliferation for cancer treatment. Nobiletin (NOB), a polymethoxyflavone phytochemical, is present abu...

(This article belongs to the Section Cell Signaling)
  • Article
  • Open Access
16 Citations
11,531 Views
15 Pages

Novel Lipidized Derivatives of the Bioflavonoid Hesperidin: Dermatological, Cosmetic and Chemopreventive Applications

  • Alessia Bino,
  • Chiara Beatrice Vicentini,
  • Silvia Vertuani,
  • Ilaria Lampronti and ,
  • Roberto Gambari,
  • Elisa Durini,
  • Stefano Manfredini and
  • Anna Baldisserotto
  • + 3 authors+ 0 author

15 December 2018

Hesperidin is one of the most important natural flavonoids, known for its antioxidant, anti-inflammatory, anti-mutagenic, and anti-hypertensive properties. Despite its various biological activities, hesperidin is rarely used in the dermo-cosmetic fie...

(This article belongs to the Special Issue Anti-aging Properties of Natural Compounds)
  • Review
  • Open Access
31 Citations
15,603 Views
22 Pages

The family of retinoic acid receptors (RARs: RARα, -β, and -γ) has remarkable pleiotropy characteristics, since the retinoic acid/RARs pathway is involved in numerous biological processes not only during embryonic development, but al...

(This article belongs to the Special Issue Chromosome and Karyotype Variation)
  • Review
  • Open Access
29 Citations
6,118 Views
14 Pages

Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?

  • Kordelia Barbullushi,
  • Nicolò Rampi,
  • Fabio Serpenti,
  • Mariarita Sciumè and ,
  • Sonia Fabris,
  • Pasquale De Roberto and
  • Nicola Stefano Fracchiolla
  • + 2 authors+ 0 author

17 June 2022

Immunotherapy is changing the therapeutic landscape of many hematologic diseases, with immune checkpoint inhibitors, bispecific antibodies, and CAR-T therapies being its greatest expression. Unfortunately, immunotherapy in acute myeloid leukemia (AML...

(This article belongs to the Special Issue Autologous Stem Cell Transplantation or New Cellular Therapies for Neoplasias)
  • Review
  • Open Access
15 Citations
7,012 Views
16 Pages

21 February 2022

We describe recent updates of existing molecular-targeting agents and emerging novel gene-specific strategies. FLT3 and IDH inhibitors are being tested in combination with conventional chemotherapy for both medically fit patients and patients who are...

(This article belongs to the Section Molecular Oncology)
  • Review
  • Open Access
17 Citations
5,938 Views
16 Pages

FLT3-mutated acute myeloid leukemia accounts for around 30% of acute myeloid leukemia (AML). The mutation carried a poor prognosis until the rise of tyrosine kinase inhibitors (TKIs). New potent and specific inhibitors have successfully altered the c...

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Editorial
  • Open Access
27 Citations
6,287 Views
9 Pages

Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives

  • Domenico Russo,
  • José Valentín Garcia-Gutierrez,
  • Simona Soverini and
  • Michele Baccarani

Ph+ chronic myeloid leukemia (CML) is a clonal myeloproliferative disease whose clinical course is characterized by progression disease from the early chronic phase (CP) to the fatal blastic phase (BP). This programmed course is closely related to th...

(This article belongs to the Special Issue Prognosis and Therapy of Chronic Myeloid Leukemia)
  • Article
  • Open Access
3 Citations
4,013 Views
11 Pages

Morphological Dynamics of Leukemia Cells on TiO2 Nanoparticle Coatings Studied by AFM

  • Jaime Andres Garcia Diosa,
  • Alejandro Gonzalez Orive,
  • Guido Grundmeier,
  • Ruben Jesus Camargo Amado and
  • Adrian Keller

22 October 2021

Coatings of modified TiO2 nanoparticles (TiO2-m) have been shown to effectively and selectively trap non-adherent cancer cells, with an enormous potential for applications in photodynamic therapy (PDT). Leukemia cells have a remarkable affinity for T...

(This article belongs to the Section Nanotechnology and Applied Nanosciences)
  • Review
  • Open Access
14 Citations
6,014 Views
13 Pages

15 March 2022

Patients with high-risk acute myeloid leukemia are offered allogeneic hematopoietic cell transplantation (allo-HCT) in first remission to reduce risk of relapse. However, disease recurrence remains the major reason of allo-HCT failure, occurring in a...

(This article belongs to the Section Cancer Therapy)
  • Review
  • Open Access
3 Citations
3,232 Views
9 Pages

Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2

  • Pau Montesinos,
  • Francesco Buccisano,
  • Thomas Cluzeau,
  • Lovisa Vennström and
  • Michael Heuser

10 May 2024

The treatment and management of acute myeloid leukemia (AML) has improved in recent decennia by targeted therapy for subgroups of patients, expanded indications for allogeneic stem cell transplantation (allo-SCT) and surveillance of residual or arisi...

(This article belongs to the Topic Myeloma and Leukemia-Challenges and Current Treatment Options)
  • Article
  • Open Access
5 Citations
2,602 Views
12 Pages

Immunopeptidome Diversity in Chronic Lymphocytic Leukemia Identifies Patients with Favorable Disease Outcome

  • Maddalena Marconato,
  • Yacine Maringer,
  • Juliane S. Walz,
  • Annika Nelde and
  • Jonas S. Heitmann

25 September 2022

Chronic lymphocytic leukemia (CLL) is characterized by recurrent relapses and resistance to treatment, even with novel therapeutic approaches. Despite being considered as a disease with low mutational burden and thus poor immunogenic, CLL seems to re...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Article
  • Open Access
91 Citations
32,310 Views
22 Pages

Thymoquinone Induces Mitochondria-Mediated Apoptosis in Acute Lymphoblastic Leukaemia in Vitro

  • Landa Zeenelabdin Ali Salim,
  • Syam Mohan,
  • Rozana Othman,
  • Siddig Ibrahim Abdelwahab and ,
  • Behnam Kamalidehghan,
  • Bassem Y. Sheikh and
  • Mohamed Yousif Ibrahim
  • + 2 authors+ 0 author

12 September 2013

There has been a growing interest in naturally occurring compounds from traditional medicine with anti-cancer potential. Nigella sativa (black seed) is one of the most widely studied plants. This annual herb grows in countries bordering the Mediterra...

(This article belongs to the Section Natural Products Chemistry)
  • Review
  • Open Access
26 Citations
7,155 Views
18 Pages

9 October 2018

Myeloid hematological malignancies are clonal bone marrow neoplasms, comprising of acute myeloid leukemia (AML), the myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), the myeloproliferative neoplasms (MPN) and systemic mastocyt...

(This article belongs to the Special Issue Histone Deacetylase Inhibitors in Health and Disease)
  • Communication
  • Open Access
5 Citations
3,615 Views
14 Pages

Influence of Human Bone Marrow Mesenchymal Stem Cells Secretome from Acute Myeloid Leukemia Patients on the Proliferation and Death of K562 and K562-Lucena Leukemia Cell Lineages

  • Fábio Alessandro de Freitas,
  • Débora Levy,
  • Cadiele Oliana Reichert,
  • Juliana Sampaio-Silva and ,
  • Pedro Nogueira Giglio,
  • Luís Alberto de Pádua Covas Lage,
  • Marco Kawamura Demange,
  • Juliana Pereira and
  • Sérgio Paulo Bydlowski
  • + 4 authors+ 0 author

Leukemias are among the most prevalent types of cancer worldwide. Bone marrow mesenchymal stem cells (MSCs) participate in the development of a suitable niche for hematopoietic stem cells, and are involved in the development of diseases such as leuke...

(This article belongs to the Section Molecular Oncology)
  • Article
  • Open Access
20 Citations
6,121 Views
9 Pages

NANOG Expression as a Responsive Biomarker during Treatment with Hedgehog Signal Inhibitor in Acute Myeloid Leukemia

  • Seiji Kakiuchi,
  • Yosuke Minami,
  • Yoshiharu Miyata,
  • Yu Mizutani and ,
  • Hideaki Goto,
  • Shinichiro Kawamoto,
  • Kimikazu Yakushijin,
  • Keiji Kurata,
  • Hiroshi Matsuoka and
  • Hironobu Minami
  • + 5 authors+ 0 author

24 February 2017

Aberrant activation of the Hedgehog (Hh) signaling pathway is involved in the maintenance of leukemic stem cell (LSCs) populations. PF-0444913 (PF-913) is a novel inhibitor that selectively targets Smoothened (SMO), which regulates the Hh pathway. Tr...

(This article belongs to the Special Issue Cancer Stem Cells)
  • Article
  • Open Access
46 Citations
6,156 Views
23 Pages

C60 Fullerene as an Effective Nanoplatform of Alkaloid Berberine Delivery into Leukemic Cells

  • Anna Grebinyk,
  • Svitlana Prylutska,
  • Anatoliy Buchelnikov,
  • Nina Tverdokhleb and ,
  • Sergii Grebinyk,
  • Maxim Evstigneev,
  • Olga Matyshevska,
  • Vsevolod Cherepanov,
  • Yuriy Prylutskyy and
  • Marcus Frohme
  • + 9 authors+ 4 authors

A herbal alkaloid Berberine (Ber), used for centuries in Ayurvedic, Chinese, Middle-Eastern, and native American folk medicines, is nowadays proved to function as a safe anticancer agent. Yet, its poor water solubility, stability, and bioavailability...

  • Article
  • Open Access
16 Citations
4,678 Views
13 Pages

15 August 2019

Betula platyphylla bark has been evaluated for the treatment of dermatitis, inflammatory conditions, and cancer. Diarylheptanoids are the major constituents of the B. platyphylla bark and possess various pharmacological effects. Our previous study co...

(This article belongs to the Section Natural Products Chemistry)

of 2